Post-Traumatic Stress Disorder (PTSD) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$17995

This report covers the 7MM and provides an Excel-based forecast model for the Post-Traumatic Stress Disorder market through 2034.

Trauma-based psychotherapy is widely considered to be the first line of therapeutic intervention for PTSD patients, with pharmacotherapy often used as an adjunct to psychotherapy. Only two drugs, both SSRIs, have been approved by the FDA for the treatment of PTSD: Zoloft (sertraline) and Paxil (paroxetine). The central issue with pharmacotherapy in PTSD is a lack of efficacy of available treatments. The PTSD market across the 7MM was valued at $1.2 billion in the 2024 baseline year and is projected to grow at a compound annual growth rate (CAGR) of 15.8%, reaching $5.4 billion by 2034. A key driver of growth will be the launch of eight late-stage pipeline products, including the first psychedelic therapeutics for PTSD.

Scope

Overview of Post-Traumatic Stress Disorder (PTSD), including epidemiology, symptoms, diagnosis, and disease management.

Annualized PTSD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PTSD market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PTSD. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the 7MM PTSD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM PTSD therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the PTSD therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

GSK plc
Eli Lilly and Co
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Seelos Therapeutics, Inc.
Ananda Scientific Inc
Lykos Therapeutics
Idorsia Pharmaceutical Ltd
Compass Pathways Plc
Transcend Therapeutics Inc
Neuphoria Therapeutics Inc

Table of Contents

Table of Contents

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Disease Overview

3.1. Overview of PTSD

3.2. Pathophysiology of PTSD

3.3. Classification of PTSD

3.4. PTSD SWOT Analysis

4. Epidemiology

4.1. 12-Month Total Prevalent Cases of PTSD, Men and Women, Ages ≥ 18 Years, 2024‒34

4.2. Age-Specific 12-Month Total Prevalent Cases of PTSD, Men and Women, 2024

4.3. Sex-Specific 12-Month Total Prevalent Cases of PTSD, Ages ≥18 Years, 2024

4.4. 12-Month Total Prevalent Cases of PTSD by Disease Status, Men and Women, Ages ≥18 Years, 2024

4.5. Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD

4.6. Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD by Disease Status

4.7. Sources Used to Forecast the 12Month Total Prevalent Cases of PTSD by Military Status

4.8. Sources and Methodology – 12-Month Total Prevalent Cases of PTSD

4.9. Sources and Methodology – 12-Month Total Prevalent Cases of PTSD by Disease Status

5. Current Treatment Options

5.1. Treatment Paradigm

5.2. Current Treatment Options

5.3. Product Profile: Pfizer’s Zoloft/Besitran/Lustral (sertraline)

5.4. Product Profile: GSK’s Paxil/Deroxat/Seroxat/Aropax (paroxetine)

5.5. Product Profile: Eli Lilly’s Prozac (fluoxetine)

5.6. Product Profile: Pfizer’s Effexor XR/Effexor/Effexor XL/Vandral (venlafaxine)

5.7. Product Profile: Pfizer’s Minipress/Hypovase (prazosin)

5.8. Patient Flow: PTSD in 2024 Across 7MM

6. Unmet Needs and Opportunities

6.1. Unmet Needs in PTSD

6.2. New Therapeutic Options with Improved Efficacy

6.3. Increase Access to Psychotherapy

6.4. Treatment Options with Improved Side-Effect Profiles

6.5. More consistent diagnostic and treatment guidelines

7. R&D Strategies

7.1. Trends in Clinical Trial Design in PTSD

7.2. Regulatory Challenges for Psychedelic Treatments

7.3. Timeline of Regulatory Challenges for Lykos Therapeutics

7.4. Trends in Deal-Making in PTSD

8. Pipeline Assessment

8.1. PTSD Pipeline Overview

8.2. Late-Stage Pipeline Agents for PTSD

8.3. Product Profile: Otsuka Pharmaceutical’s Rexulti (brexpiprazole)

8.4. Product Profile: Neuphoria Therapeutics’ BNC-210

8.5. Product Profile: Idorsia Pharmaceutical’s Quviviq (daridorexant)

8.6. Product Profile: Ananda Scientific’s Nantheia ATL5 (cannabidiol)

8.7. Product Profile: Transcend Therapeutics’ TSND-201 (methylone)

8.8. Product Profile: Lykos Therapeutics’ midomafetamine hydrochloride

8.9. Product Profile: Seelos Therapeutics’ Ereska (ketamine hydrochloride)

8.10. Product Profile: Compass Pathways’ COMP360 (psilocybin)

8.11. PTSD: Clinical Trials (Phase II/III) Overview

9. Market Outlook

9.1. PTSD Market Forecast

9.2. Market Drivers and Barriers

10. Appendix

10.1. Primary Research: KOL Information

10.2. Primary Research: High Prescriber Survey Information

10.3. Bibliography

10.4. About the Authors

11. Contact Us

Post-Traumatic Stress Disorder (PTSD) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Post-Traumatic Stress Disorder (PTSD) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034 in real time.

  • Access a live Post-Traumatic Stress Disorder (PTSD) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.